[Preliminary study on Id4 as a reporter for all patients before relapse].
This study was purposed to investigate the feasibility of inhibitor of DNA banding 4 (Id4) as a reporter for acute lymphoblastic leukemia (ALL) patients before their clinical relapse. Id4 promoter at methylation status was detected by MS-PCR in bone marrow samples from the ALL patients who had been in their complete remission (CR) for 6 to 8 months with follow-up period of at least three months. The results showed that Id4 methylation were found in 20 out of all 32 patients (62.5%). The remainder 12 patients were fourd Id4 unmethylated, 1 case out of whom relapsed within the next 3-month of follow-up (8.33%), while 10 out of 20 patients (50%) with Id4 methylation relapsed within the same follow-up period. Existence of high risk factors at de novo diagnosis didn't correlated with the Id4 methylation status. In conclusion, Id4 could be regard as a reporter for ALL patients before their relapse.